奥西默替尼
医学
表皮生长因子受体
仿形(计算机编程)
肿瘤科
内科学
癌症研究
受体
埃罗替尼
计算机科学
操作系统
作者
Zofia Piotrowska,Mok-Ryeon Ahn,Y-K. Pang,S.H. How,K. Sang-We,P.J. Voon,D.L. Cortinovis,J. De Castro Carpeño,M. Tiseo,D. Rodriguez Abreu,S.S. Ramalingam,J. Li,L. Servidio,S. Sadow,R.J. Hartmaier,B.C. Cho
标识
DOI:10.1016/j.annonc.2022.10.398
摘要
Osimertinib – a 3rd-generation EGFR-TKI – is the preferred 1L treatment for EGFRm advanced NSCLC; however, pts can eventually develop progressive disease (PD). ELIOS (NCT03239340) characterised resistance mechanisms to 1L osimertinib. To our knowledge, this is the first prospective study with a primary objective comparing paired baseline and post-PD tumour tissue biopsies.
科研通智能强力驱动
Strongly Powered by AbleSci AI